Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection

尽管每年都在努力接种疫苗，但甲型流感病毒(IAV)仍然是一个全球卫生问题。临床干预措施 能否预防与严重IAV感染相关的免疫病理和细胞因子风暴是当务之急 需要，特别是可以在感染的后期阶段启动的方法。从调查中获得的知识 拟议的研究将促进基于IL-2的治疗方法的新应用的开发 治疗严重呼吸道病毒感染，并促进其作为佐剂的潜在用途，以促进普及， 接种疫苗后的IAV特异性免疫。

Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal, IAV-specific immunity following vaccination.